SELL and chronic obstructive pulmonary disease: Indeed, Revotar Biopharmaceuticals AG is developing the drug under license from Encysive, which is a CD62L antagonist (TBC-1269) for the potential treatment of asthma, COPD, VILI, ALI and ARDS.